(Q36242608)

13 August 2017

1 reference

title

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection (English)

1 reference

13 August 2017

10

Faiez Zannad

1 reference

13 August 2017

Massimo Volpe

8

0 references

Luis Miguel Ruilope

object named as

Luis M Ruilope

1

0 references

Giuseppe Mancia

4

object named as

Giuseppe Mancia

1 reference

13 August 2017

7

Thomas Unger

1 reference

13 August 2017

Enrico Agabiti Rosei

2

1 reference

13 August 2017

George L Bakris

3

1 reference

13 August 2017

Neil R Poulter

5

1 reference

13 August 2017

Stefano Taddei

6

1 reference

13 August 2017

Bernard Waeber

9

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

14

1 reference

13 August 2017

issue

4

1 reference

13 August 2017

page(s)

196-209

1 reference

Selected major risk factors and global and regional burden of disease

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

What have we learned from the current trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Angiotensin II receptor blockers: review of the binding characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Differential effects of angiotensin AT1 and AT2 receptors on the expression, translation and function of the Na+-H+ exchanger and Na+-HCO3- symporter in the rat heart after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Mechanisms for the clinical benefits of angiotensin II receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

A population-based survey of drug treatment efficacy by the French National Committee for the Control of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Clinicians and patients with hypertension: Unsettled issues about compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Tolerability and treatment compliance with angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Compliance and persistence with newer antihypertensive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

The epidemiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Prognostic significance of left ventricular mass change during treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effect of AT1 receptor blockade on endothelial function in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Different effect of antihypertensive drugs on conduit artery endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effect of captopril and enalapril on endothelial function in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effect of angiotensin II and vasopressin on acquisition and extinction of conditioned avoidance in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Targeting people with pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Diabetes and cardiovascular events in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Hypertension in the metabolic syndrome and diabetes: pathogenesis, clinical studies, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

The effects of valsartan on insulin sensitivity in patients with primary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050500230227

10.1080/08037050500230227

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference